Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Lanthier

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|June 18, 2019
An Analysis of Follow-On Development in New Drug Classes, January 1986-June 2018Michael L Lanthier, Kirk W Kerr, Kathleen L Miller
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 26, 2020
An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019Nidhi Dheman, Nicole Mahoney, Edward M Cox, et al.
JAMA|January 23, 2014
Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012Leonard V Sacks, Hala H Shamsuddin, Yuliya I Yasinskaya, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 23, 2025
Measuring the First Mover Advantage in US Biosimilar MarketsJ Daniel McGeeney, Aylin Sertkaya, Samantha A McCormick, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|June 18, 2019
An Analysis of Follow-On Development in New Drug Classes, January 1986-June 2018Michael L Lanthier, Kirk W Kerr, Kathleen L Miller
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 26, 2020
An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019Nidhi Dheman, Nicole Mahoney, Edward M Cox, et al.
JAMA|January 23, 2014
Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012Leonard V Sacks, Hala H Shamsuddin, Yuliya I Yasinskaya, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 23, 2025
Measuring the First Mover Advantage in US Biosimilar MarketsJ Daniel McGeeney, Aylin Sertkaya, Samantha A McCormick, et al.
Pageof 1